OTCMKTS:EVTCY Evotec (EVTCY) Stock Forecast, Price & News $11.67 +0.49 (+4.38%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$11.54▼$11.6750-Day Range$8.95▼$11.1952-Week Range$14.22▼$26.57Volume16,511 shsAverage Volume2,407 shsMarket Capitalization$3.85 billionP/E Ratio28.46Dividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestProfileChartCompetitorsFinancialsHeadlinesSEC FilingsShort Interest About Evotec (OTCMKTS:EVTCY) StockEvotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Read More Receive EVTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Email Address EVTCY Stock News HeadlinesMay 30, 2023 | finance.yahoo.comIs There Now An Opportunity In Evotec SE (ETR:EVT)?May 14, 2023 | finance.yahoo.comEvotec SE (ETR:EVT) Shares Could Be 37% Below Their Intrinsic Value EstimateJune 3, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 13, 2023 | finanznachrichten.deEvotec SE: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023May 12, 2023 | investing.comEvotec SE ADR (EVO) Earnings Dates & ReportsMay 10, 2023 | investing.comEvotec SE ADR (EVO)May 9, 2023 | finanznachrichten.deEvotec SE: Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial ManufacturingApril 10, 2023 | finance.yahoo.comEvotec SE Provides Update on Cyber AttackJune 3, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>February 10, 2023 | finanznachrichten.deEvotec SE: Evotec Receives € 150 m Loan from European Investment BankJanuary 31, 2023 | markets.businessinsider.comEQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributionDecember 22, 2022 | ca.finance.yahoo.comWith 47% ownership, Evotec SE (ETR:EVT) has piqued the interest of institutional investorsDecember 17, 2022 | finanznachrichten.deEvotec SE: Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers SquibbSeptember 21, 2022 | finanznachrichten.deEvotec SE: Just - Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies ProgramSeptember 20, 2022 | markets.businessinsider.comEvotec: US Unit Gets $49.9 Mln Antibodies Contract From U.S. Department Of DefenseSeptember 17, 2022 | finanznachrichten.deEvotec SE: Evotec Initiates Ground-Breaking for New Biologics Facility J.POD Toulouse, FranceAugust 13, 2022 | seekingalpha.comEvotec SE's (EVOTF) CEO Dr. Werner Lanthaler on Q2 2022 Results - Earnings Call TranscriptAugust 11, 2022 | nasdaq.comEvotec Slips To Loss In Q3, Revenues Rise; Lifts FY22 Revenue View, Backs Adj. EBITDA ForecastAugust 11, 2022 | markets.businessinsider.comDGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updatesAugust 11, 2022 | finance.yahoo.comEvotec SE Reports Results for the First Half-year 2022 and Provides Corporate UpdatesAugust 10, 2022 | finanznachrichten.deEvotec SE: Just - Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303May 11, 2022 | nasdaq.comEvotec Q1 Adj. EBITDA Down, Revenues UpApril 12, 2022 | apnews.comEvotec SE Fiscal Year 2021 Results: ‘Setting the Pace’ on the Data-Driven R&D Autobahn to CuresApril 12, 2022 | finanznachrichten.deEvotec AG: Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to CuresApril 12, 2022 | seekingalpha.comEvotec SE reports FY resultsApril 12, 2022 | nasdaq.comEvotec FY21 Net Income Surges, Operating Result Down; Sees Higher Group Revenues In FY22March 2, 2022 | markets.businessinsider.comEvotec Confirms Goals Of Action Plan 2025See More Headlines EVTCY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVTCY Company Calendar Today6/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:EVTCY CUSIPN/A CIK1412558 Webwww.evotec.com Phone(494) 056-0810Fax49-40-5608-1222Employees3,572Year Founded1993Profitability EPS (Most Recent Fiscal Year)$0.41 Trailing P/E Ratio28.46 Forward P/E RatioN/A P/E GrowthN/ANet Income$7.14 million Net Margins20.85% Pretax Margin23.90% Return on Equity16.02% Return on Assets7.81% Debt Debt-to-Equity Ratio0.53 Current Ratio2.57 Quick Ratio2.50 Sales & Book Value Annual Sales$572.16 million Price / Sales6.74 Cash Flow$0.11 per share Price / Cash Flow105.53 Book Value$2.52 per share Price / Book4.63Miscellaneous Outstanding Shares330,221,000Free FloatN/AMarket Cap$3.85 billion OptionableNot Optionable Beta0.98 Social Links Key ExecutivesWerner LanthalerChief Executive OfficerCraig L. JohnstoneChief Operating Officer & Member-Management BoardEnno SpillnerChief Financial OfficerCord E. DohrmannChief Scientific OfficerVolker BraunSVP, Head-Investor Relations & ESGKey CompetitorsArrowhead PharmaceuticalsNASDAQ:ARWRUltragenyx PharmaceuticalNASDAQ:RAREBlueprint MedicinesNASDAQ:BPMCCytokineticsNASDAQ:CYTKProthenaNASDAQ:PRTAView All Competitors EVTCY Stock - Frequently Asked Questions How have EVTCY shares performed in 2023? Evotec's stock was trading at $8.09 at the start of the year. Since then, EVTCY stock has increased by 44.3% and is now trading at $11.67. View the best growth stocks for 2023 here. When did Evotec's stock split? Evotec shares split on the morning of Wednesday, October 20th 2021. The 3-1 split was announced on Wednesday, October 20th 2021. The newly minted shares were issued to shareholders after the market closes on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What is Evotec's stock symbol? Evotec trades on the OTCMKTS under the ticker symbol "EVTCY." How do I buy shares of Evotec? Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Evotec's stock price today? One share of EVTCY stock can currently be purchased for approximately $11.67. How much money does Evotec make? Evotec (OTCMKTS:EVTCY) has a market capitalization of $3.85 billion and generates $572.16 million in revenue each year. The company earns $7.14 million in net income (profit) each year or $0.41 on an earnings per share basis. How many employees does Evotec have? The company employs 3,572 workers across the globe. Does Evotec have any subsidiaries? The following companies are subsidiares of Evotec: Aptuit, Bionamics GmbH, Cell Culture Service GmbH, Central Glass Germany, Central Glass Germany. GmbH, Compound Focus, Cyprotex, Develogen AG, Euprotec, Evotec (India) Private Ltd, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, KINAXO Biotechnologies, Oxford Asymmetry International, RENOVIS, and Rigenerand Srl.Read More How can I contact Evotec? Evotec's mailing address is Manfred Eigen Campus Essener Bogen 7, Hamburg 2M, 22419. The official website for the company is www.evotec.com. The company can be reached via phone at (494) 056-0810, via email at investorrelations@evotec.com, or via fax at 49-40-5608-1222. This page (OTCMKTS:EVTCY) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.